Analyst Price Targets — PLSE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 20, 2026 1:08 pm | Suraj Kalia | Oppenheimer | $30.00 | $22.03 | TheFly | Pulse Biosciences price target raised to $30 from $22 at Oppenheimer |
| February 6, 2026 12:39 pm | — | Mizuho Securities | $30.00 | $13.69 | TheFly | Pulse Biosciences price target raised to $30 from $25 at Mizuho |
| January 30, 2026 10:13 am | — | Mizuho Securities | $25.00 | $13.62 | TheFly | Pulse Biosciences initiated with an Outperform at Mizuho |
Latest News for PLSE
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on April 25, 2026, in Chicago, Illinois. Management will highlight the late-breaking data from its European…
Argo Wealth Advisory LLC acquired a new position in Pulse Biosciences, Inc (NASDAQ: PLSE) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 28,156 shares of the company's stock, valued at approximately $387,000. Several other large investors have
PLSE begins patient enrollment in NANOPULSE-AF pivotal study, advancing its NPS tech toward potential AF treatment approval and entry into a large cardiac market.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced the strengthening of its executive leadership team with the appointment of Liane Teplitsky as Chief Operating Officer and expanded role of Dr. David Kenigsberg as full-time Chief Medical Officer. Both the appointment of Liane…
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced enrollment of the first patients in its NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PLSE.
U.S. House Trading
No House trades found for PLSE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.